Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
141
-
Total 13F shares, excl. options
-
64.4M
-
Shares change
-
-7.99M
-
Total reported value, excl. options
-
$195M
-
Value change
-
-$24.7M
-
Put/Call ratio
-
0.5
-
Number of buys
-
83
-
Number of sells
-
-52
-
Price
-
$3.03
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q4 2024
167 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q4 2024.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 141 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64.4M shares
of 72.2M outstanding shares and own 89.21% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (14M shares), EVENTIDE ASSET MANAGEMENT, LLC (4.48M shares), BlackRock, Inc. (4.24M shares), VANGUARD GROUP INC (3.27M shares), CITADEL ADVISORS LLC (3.22M shares), Decheng Capital LLC (2.34M shares), Opaleye Management Inc. (1.77M shares), MORGAN STANLEY (1.71M shares), Almitas Capital LLC (1.63M shares), and PRIMECAP MANAGEMENT CO/CA/ (1.52M shares).
This table shows the top 141 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.